Abu Dhabi is the first location in the world to provide personalized therapy to patients with advanced breast cancer. This treatment uses genetic testing and molecular monitoring so that therapy can be adjusted to the patient's biological condition.
Launching the Philippine News Agency (PNA), Tuesday, June 30, citing a WAM report, the therapy was given under the supervision of the Abu Dhabi Department of Health to a female patient in her 40s.
The patient was diagnosed with advanced breast cancer. Genetic testing results found mutations in the ESR1 gene. This mutation is related to resistance to conventional hormone therapy and can promote disease progression.
The medical team uses circulating tumor DNA or ctDNA technology. This technology reads the tumor DNA traces from blood samples to monitor molecular changes in the patient's body.
In this way, doctors can detect signs of resistance to treatment early. Even before changes are visible through medical imaging or appear as clinical symptoms.
Noura Khamis Al Ghaithi, Deputy Minister of the Department of Health Abu Dhabi, said the future of health services will increasingly rely on prevention, early detection, and faster intervention.
He said that targeted therapy was in line with Abu Dhabi's efforts to build technologically advanced health services and access to cutting-edge treatment.
According to PNA, Professor Humaid Al Shamsi assessed that molecular diagnostics, artificial intelligence, and advanced analysis tools are important to be applied in clinical practice.
He said that continuous molecular monitoring helps medical personnel make more appropriate therapeutic decisions according to the biological characteristics of each patient.
The study found this new therapeutic approach reduced the risk of developing the disease by 56 percent compared to continuing conventional hormone therapy.
Experts consider periodic ctDNA monitoring to be an important advance in breast cancer treatment. Doctors can make decisions based on molecular changes before the disease is visible in the usual way.
This development is expected to contribute to the advancement of personalized oncology and precision medicine, especially in the use of molecular data to determine more appropriate therapies for patients.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
